Ipsen shares fall after earlier-than-expected FDA approval of Somatuline generic rival
The Wall Street Journal reports that the newly approved generic competes with Ipsen’s flagship Somatuline hormone drug.
TLDR
Ipsen’s stock fell sharply after the FDA approved a generic competitor to its flagship Somatuline hormone drug, The Wall Street Journal reports. The approval came earlier than expected.
Combined views
65.9K
1 Source, first seen 9d ago
19 likes3 comments4 saves2 reposts